Heron Therapeutics reported a strong Q3 2025, generating net revenues of $38.2 million and achieving adjusted EBITDA of $1.5 million, highlighting significant growth in its acute care portfolio.

• Achieved 49% year-over-year growth in ZYNRELEF net sales, reaching $9.3 million in Q3 2025.
• APONVIE sales surged 173% year-over-year, totaling $3 million, with a dedicated sales team now deployed.
• Implemented successful initiatives, including the CrossLink Ignite program and the introduction of a product-specific J-code for ZYNRELEF, enhancing distributor engagement and reimbursement processes.
• Continued strong performance in CINVANTI, maintaining steady demand despite competitive pressures.
• Year-to-date revenues of $114.3 million, with positive momentum projected to continue into Q4 and beyond.